Author Archives: admin


What is Mantle Cell Lymphoma and How Is It Treated? – Dana-Farber Cancer Institute

Last Updated on January 10, 2020

Medically reviewed by Ann S. LaCasce, MD, MMSc

Mantle cell lymphoma is a rare, often aggressive form of non-Hodgkin lymphoma (NHL), a cancer that involves white blood cells known as lymphocytes, which help protect the body from disease. It is named for its origins in the mantle zone a ring of cells within the lymph nodes where B cells (a type of lymphocyte) grow and take on specialized functions. It comprises about 6% of all cases of NHL, usually arises during an individuals early 60s, and is more common in men than women.

The most common symptoms of mantle cell lymphoma include:

At the time of diagnosis,nearly all patients have disease that has spread beyond its initial site.

For most patients, the cause of the disease is unknown, but rates are higher among farmers and people from rural areas.

Itoccurs when B lymphocytes acquire genetic mutations that alter their functionand growth. One such abnormality, found in 90% of cases, causes B lymphocytesto overproduce cyclin D1, a protein that spurs the cells growth. Othermutations can interfere with B cells ability to produce infection-fightingantibodies, leaving patients vulnerable to certain diseases.

A definitive diagnosis requires a biopsy of an affected lymph node or other involved tissue.

Doctors use a variety of scans to determine the diseases stage, or how far it has advanced. These include:

Treatment for mantle cell lymphoma varies depending on patients age and overall health and the stage of the disease. Patients who have yet to develop symptoms and who have a relatively small amount of slow-growing disease may be recommended for active surveillance close monitoring of their health through regular checkups and lab tests. When lymphoma-related symptoms appear or tests show a worsening of the disease, active treatment may begin.

The initial treatment for aggressive mantle cell lymphoma in younger patients often includes a combination of chemotherapy drugs in conjunction with an antibody-based treatment, often followed by a stem cell transplant using patients own stem cells. Older, less-fit patients may undergo less intensive chemotherapy sometimes followed by a prolonged course of antibody therapy.

Other treatments may include drugs known as BTK inhibitors such as acalbrutinib and ibrutinib, which interfere with lymphoma cells internal growth signals.

In patients who relapse after treatment or dont respond to initial treatment, a variety of options may be available, including:

Clinical trials are currently underway of CAR T-cell therapy for patients with mantle cell lymphoma. The therapy, which uses genetically modified immune system T cells to attack tumor cells, has been shown to be effective in patients with other forms of non-Hodgkin lymphoma. Other trials are testing drugs known as bispecific antibodies, artificial proteins that can bind simultaneously to two surface proteins on cells, and targeted agents directed against specific cancer-related proteins.

Here is the original post:
What is Mantle Cell Lymphoma and How Is It Treated? - Dana-Farber Cancer Institute

Doug Richards remembered – faribaultcountyregister.com | News, Sports, Information on the Blue Earth region – Faribault County Register

Faribault County recently suffered the loss of the recently retired Honorable Judge Douglas Richards.

Since 2012, Richards battled a rare form of blood cancer known as multiple myeloma. There is no cure for the cancer and since his cancer prognosis eight years ago, Richards fought tooth and nail through chemotherapy treatments and stem cell transplants which can greatly compromise the immune system.

Judge Richards became the Faribault County District Court judge back in 1995, and prior to that, was an attorney in Faribault County for many years. He earned his undergraduate degree at Hamline University and earned his degree in law at the William Michell College of Law.

Orv Terhark, Faribault County District Court stenographer for many years, now retired, worked alongside Richards.

"Judge Richards has always had remarkable patience," Terhark reflected of his friend. "It was important to him that all litigants in his courtroom had equal and ample time to be heard, no matter how hectic our schedule was."

Retired attorney Chuck Frundt recalls the State of Minnesota was considering lessening the number of judges across the state, and that included Faribault County's district judge.

"We attorneys were worried about what would happen,"?says Frundt. "Many of us Faribault County attorneys stood together and supported Judge?Richard's judgeship. We wrote letters, we called Governor Arne Carlson to let them know we needed Judge Richards."

And the state listened. Faribault County did not lose its district judge when the state lessened its judgeships.

"He was a good judge, a fair judge," says Frundt. "And when he was an attorney, as a competing attorney, he was good, he was congenial. A solid person to have in the courtroom."

Chuck's wife Rita Frundt recalls Judge Richards saying at his retirement party that he liked being an attorney, but loved being a judge.

Current Faribault County District Judge Troy Timmerman said he spent his entire career under Judge Richards when he moved to the county in 1994.

"He had a quiet strength about him," says Judge Timmerman. "He was able to maintain control of the courtroom while still remaining approachable."

"I worked with Judge Richards for so many years, and regardless of who was involved, or how it panned out in the courtroom, he always treated everyone with dignity and respect," says Faribault County's victim witness coordinator Deb Weiderhoft. "The loss of Judge Richards is a great one that can be felt throughout the community."

Before his death, Judge Richards spent many years participating in the local Relay For Life event. In 2017, the Faribault County Register had the opportunity to speak with him about his battle with cancer.

"The best thing in life is to keep a positive focus on things," Richards told the Register. "There's no need to think negative thoughts, stay positive. Keeping positive is not going to cure your disease, but it will give you better days, and it is important to make every day count."

Read the original:
Doug Richards remembered - faribaultcountyregister.com | News, Sports, Information on the Blue Earth region - Faribault County Register

The F.D.A. Is in Trouble. Heres How to Fix It. – The New York Times

Fortunately, options for fortifying the F.D.A. abound. For instance, laws that would make it easier for regulators to police the cosmetics industry and to hold medical device companies to account have been floating through Congress for years. A group of former F.D.A. commissioners last year proposed an even bolder fix: Restore the agencys autonomy by extracting it from the Department of Health and Human Services. The F.D.A.s decisions used to be final, but for decades now they have been subject to layers of political interference. Making the agency independent, as the Federal Reserve and the Social Security Administration are, could help reverse that trend.

But for these or other worthy ideas to get a fair hearing, Congress will have to step in, and the president and the electorate will need to come to terms with the essential role of regulations in protecting the nations food and drug supply.

In the meantime, the challenge of steering the F.D.A. will fall to Dr. Hahn. He will not have nearly enough resources to carry out the agencys stated mission no commissioner ever does. But he will not be completely powerless, either. Here are four things Dr. Hahn would do well to keep in mind as he takes the reins.

Stay vocal. Dr. Hahns predecessor, Dr. Gottlieb, managed to keep a spotlight on his chosen priorities namely e-cigarette regulations and generic drug development with a relentless and multifaceted public messaging campaign. He tweeted, he blogged, he gave speeches and he communicated openly and regularly with the press. Dr. Gottlieb did not achieve all of his goals in fact his e-cigarette strategy backfired, badly. But he made the F.D.A. less opaque, and he gave the agency an urgently needed voice. Dr. Hahn will have an easier time defending the agency, and keeping it relevant, if he fosters the same transparency.

Slow down on drug and device approvals. The F.D.A. has made several compromises in recent years such as accepting real world or surrogate evidence in lieu of traditional clinical trial data that have enabled increasingly dubious medical products to seep into the marketplace. Dr. Hahn ought to take a fresh look at some of these shifting standards and commit to abandoning the ones that dont work. That will almost certainly mean that the approval process slows down and thats O.K.

Stand up for science. As reporting from the medical news website Stat and other outlets suggests, the F.D.A. has become too susceptible to outside pressure. Regulators approved a powerful new opioid at the Department of Defenses urging, fast-tracked a dubious antidepressant after President Trump praised it, and reversed its decision to reject a muscular dystrophy drug after patient groups complained loudly. Such kowtowing hardly inspires confidence. Scientific evidence (or the lack thereof) needs to be the deciding factor in any final regulations from the F.D.A. That means saying no to politicians and drug and device makers as well as patients groups when their demands are not supported by the agencys own findings. It also means holding companies to account when they fail to complete postmarket studies, or when their products prove faulty or dangerous.

Follow through on existing commitments. The F.D.A. has yet to issue guidelines for the regulation of increasingly popular CBD products after promising to do so by the end of 2019. E-cigarette makers are supposed to submit their applications for market approval to the agency by May. And a regulatory grace period that the agency granted to so-called stem cell clinics back in 2017 is set to expire this year; when it does, regulators will need to figure out how to police nearly 1,000 businesses selling injections and other treatments that have not proved to work and that have already caused some patients serious harm. Dr. Hahn would build a lot of good will if he showed the F.D.A.s critics and the public at large that he takes all of these deadlines seriously.

Read the rest here:
The F.D.A. Is in Trouble. Heres How to Fix It. - The New York Times

Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami – GlobeNewswire

Miami, FL, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The formal ceremony of the 2020 Stem Cell and Regenerative Medicine Action Awards will take place at a gala reception and dinner on January 23, during the 15th annual World Stem Cell Summit (WSCS) at the Hyatt Regency in Miami. Since 2005, the nonprofit Regenerative Medicine Foundation (RMF) (formerly Genetics Policy Institute) has recognized the stem cell and regenerative medicine community's leading innovators, leaders, and champions through its annual awards reception.

Bernard Siegel, Executive Director of Regenerative Medicine Foundation and founder of the World Stem Cell Summit, said, The 2020 Action Awards will recognize three important organizations that are positively impacting the emerging field of regenerative medicine. We will also honor a retired Major General, who has capped off his military and diplomatic career by promoting the cause of world peace through medicine. All of these distinguished honorees will be recognized for their devotion to improving health and developing cures through advocacy, innovation, leadership and inspiration. In addition, the wounded warrior veterans community of South Florida will also receive special recognition at the event.

Meet the 2020 Stem Cell & Regenerative Medicine Action Award Honorees:

Innovation Award: With the motto, We will not rest until we find a cure, the Cystic Fibrosis Foundation is geared towards the successful development and delivery of treatments, therapies and a cure for every person with cystic fibrosis. CF Foundation has added decades to the lives of people with the disease as a direct result of advances in treatment and care made possible through its innovative business model- venture philanthropy. The Foundation recently unveiled its Path to a Cure research agenda aimed at addressing the root genetic cause of the disease and is currently funding industry programs aimed at gene delivery with the goal of progressing into clinical studies in 2021.

Inspiration Award: Emily Whitehead Foundation is a nonprofit organization committed to raising funds to invest in the most promising pediatric cancer research. Tom and Kari Whitehead founded EWF in honor of their daughter Emily, the first child in the world to receive CAR T-cell therapy, training her own cells to fight cancer. Her inspiring story focused public attention on thepotential for cancer immunotherapy to transform cancer treatment,as well as the need to support lifesaving cancer immunotherapy research. The foundation provides support to pediatric cancer patients and promotes awareness of the disease through education and sharing other inspiring stories.

Advocacy Award: Gift of Life Marrow Registry was established in 1991 by Jay Feinberg and his family after Jay received a life-saving bone marrow transplant. Gift of Life is dedicated to saving lives and facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, sickle cell and other diseases. In 2019, Gift of Life opened the worlds first apheresis center fully integrated within a registry, the Dr. Miriam and Sheldon G. Adelson Gift of Life-Be The Match Stem Cell Collection Center. With the collection center and rapidly expanding donor database, Gift of Life will launch a biobank to advance cellular therapies using allogeneically sourced cells in 2020.

Leadership Award: Ret. Major General Bernard Burn Loeffke, PhD (US Military) is a highly decorated Special Forces officer, diplomat and medical officer.He survived two helicopter crashes and was wounded in combat. After the Vietnam War, he served as the Army Attach at theU.S. Embassy in Moscow, first Defense Attach at the U.S Embassy in Beijing, a staff officer in theWhite House, and Director of the Commission onWhite House Fellows. His last command was Commanding General of Army South. After 35 years in the military, he became a medical officer traveling the world on relief missions to third and fourth world countries. Presently, at age 85, he champions the hydrocephalus and wounded warrior communities. He continues to serve as an inspiration and supporter of building peaceful international relations through medical partnerships and played a pivotal role as a keynote speaker at the inaugural 2019 World Stem Cell Summit CHINA.He is called the Peace General in Latin America. In China, he is simply known as The General, our Friend.

To learn more about past honorees and details for sponsoring or attending the upcoming 2020 Stem Cell and Regenerative Medicine Action Awards dinner, please visit, https://www.worldstemcellsummit.com/stem-cell-action-awards/

About the World Stem Cell Summit (WSCS)

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: http://www.worldstemcellsummit.com.

About the Regenerative Medicine Foundation (RMF)

The nonprofit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF unites the worlds leading researchers, medical centers, universities, labs, businesses, funders, policymakers, experts in law, regulation and ethics, medical philanthropies, and patient organizations. We maintain a trusted network of leaders and pursue our mission by producing our flagship World Stem Cell Summit series of conferences and public days, honoring leaders through the Stem Cell and Regenerative Medicine Action Awards, supporting our official journal partner STEM CELLS Translational Medicine (SCTM), promoting solution-focused policy initiatives both nationally and internationally and creating STEM/STEAM educational projects. For more information about RMF, please visit: http://www.regmedfoundation.org.

See original here:
Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami - GlobeNewswire

SNACS: The FAANG Of The Roaring 20s – Yahoo Finance

The roaring 20s are upon us, and the investment opportunities set in front of us are exhilarating. This new decade has a lot in store for us with tech as the driving force behind it.

FAANG was the acronym that drove the stock market to continuously new highs over the past decade: Facebook (FB), Amazon (AMZN), Apple (AAPL), Netflix (NFLX), and Google aka Alphabet (GOOGL). This is an acronym that I am sure you are familiar with. These stocks exponential returns may be exhausted, and a new set of equities are ready to take their place. It is time to look for the new FAANG.

When assessing market-shifting companies, you need to look for firms with an exciting product offering characterized by longevity and a substantial total addressable market (TAM). Firms with savvy management teams that are able to navigate through both the best and worst times nimbly.

I have chosen a new acronym of stocks that I believe could change the world in the roaring 20s. The companies include Crispr (CRSP), Sea Limited (SE), Alibaba (BABA), Nvidia (NVDA), and Splunk (SPLK) or SCANS, as I like to call it.

Here I will give a brief introduction of each stock and explain why I believe these shares will drive the market in this new decade.

Sea Limited (SE)

Sea is the leading internet company in Southeast Asia and Taiwan. These economies are digitalizing at an exponential rate, and Sea is well-positioned to take on the quickly expanding addressable market. The company operates three market leader segments, including an ecommerce platform, a digital entertainment division, and a digital payment company (Shopee, Garena, and AirPay, respectively).

The internet economy in Southeast Asia has tripled in the past 5 years to $100 billion and is expected to triple again by 2025 to $300 billion. Sea is growing at an even faster rate, with year-over-year topline appreciation in the high triple-digit percentages as the company continues to take an increasing amount of market share.

Sea Limited is going to be the tech powerhouse that helps turn the third world economies of Southeast Asia and Taiwan into digitalized world markets.

CRISPR (CRSP)

CRISPR is a biomedical firm that is on the verge of changing the world. This company can edit an individuals DNA, an achievement that is going to change modern medicine. This technology could be used to cure almost any disease if it is successfully implemented. What CRISPRs gene therapy does is splice out the bad or disease driving DNA and add healthy strands. The company is also a leader in regenerative stem-cell medicine, which could save the lives of 100s of thousands.

CRISPR has an established portfolio of life-changing therapies in its pipeline at various stages of development. Hemoglobinopathy is the closest to commercially viable and is currently in clinical trials. If it passes clinical trials, I see this stock jumping substantially.

These shares are still a risky asset considering the possibility that none of its gene-therapies make it past the clinical stage. Based on early trials, it appears that the therapy does indeed work, and this potential has begun to be priced into CRSP. The stock has appreciated 350% since it went public in late 2016, and I believe that this is just the beginning of its growth. The ability to change an individuals DNA is going to change the world of medicine.

Alibaba (BABA)

The Amazonof the East has been driving substantial growth, but I dont believe that investors are correctly valuing Alibabas fundamentals. BABA is trading at roughly 1/3rd of Amazons forward P/E valuation (seen below), despite achieving wider margins, stronger profitable, and a greater growth outlook. Alibaba is operating in one of the worlds largest and fastest-growing consumer markets (China).

Story continues

Alibaba controls not only Chinas ecommerce market but also its cloud computing space with a 47% market share. Its cloud computing space has the most room to run as Chinas cloud infrastructure continues to expand at an exponential rate high double-digit to triple-digit percentages.

Alibaba still has some geopolitical risk due to the US-China trade war, but as far as this next decades biggest equity drivers, I would replace AZMN with BABA in my portfolio.

Nvidia (NVDA)

This is the most exciting chip maker in the world today. Nvidia is known for the invention of the GPU, which is a chip original purposed for image rendering, but Nvidia has taken its capabilities far beyond this. Nvidias chips are hyper-fast and slowly becoming smarter as the technology develops. Its chips are becoming a necessity in data centers and are an essential element of AI development. I believe that one of Nvidias integrated circuits will be apart of the first true AI, which is going to change the world.

Nvidia is also leveraging 5G with its anticipated cloud gaming platform. Like cloud computing is the future of business data and analytics, cloud gaming is the future of gaming. Nvidia is making a big bet in this field with its cloud platform, GeForce NOW. This platform allows gamers to use their Macs or PCs for gaming anywhere with the high-speed, low-latency technology of Nvidias GPUs without needing Nvidias hardware locally.

Nvidia is undoubtedly a company of the future, and despite its 4-digit gains over the past decade, I believe that this stock still has legs to run. I dont think that the company has scratched the surface of what its chips could do.

Splunk (SPLK)

Splunk is a platform that helps companies utilize real-time machine data for collection, indexing, and alerts, allowing companies to uncover actionable insight from this data no matter the source or format. The company is leveraging AI and machining learning for forecasting and anticipative decision making.

Real-time data management is becoming increasingly necessary in business across industries as this digital age makes speed a competitive advantage. Splunk is well-positioned to take on the massive addressable market that is yet to recruit Splunks services. This firm is well-suited to transform the way our economy utilizes real-time data.

Take Away

The market driving stocks will undoubtedly make excellent long-term investments for the roaring 20s. SCANS will be a force to be reckoned with in this next decade. Short term volatility in these stocks shouldnt cause you to shy away from their long-term potential. I believe we may be on the edge of a market correction, so if you are worried about short-term earnings, I may wait for a pullback. If you are a long-term investor that is willing to ride this decades waves, I wouldnt hesitate to pull the trigger on these stocks.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. Theyre also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Click to get this free report Splunk Inc. (SPLK) : Free Stock Analysis Report Sea Limited Sponsored ADR (SE) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report Alphabet Inc. (GOOGL) : Free Stock Analysis Report Facebook, Inc. (FB) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report Amazon.com, Inc. (AMZN) : Free Stock Analysis Report Apple Inc. (AAPL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

Read the original post:
SNACS: The FAANG Of The Roaring 20s - Yahoo Finance

20 Technology Metatrends That Will Define the Next Decade – Singularity Hub

In the decade ahead, waves of exponential technological advancements are stacking atop one another, eclipsing decades of breakthroughs in scale and impact.

Emerging from these waves are 20 metatrends likely to revolutionize entire industries (old and new), redefine tomorrows generation of businesses and contemporary challenges, and transform our livelihoods from the bottom up.

Among these metatrends are augmented human longevity, the surging smart economy, AI-human collaboration, urbanized cellular agriculture, and high-bandwidth brain-computer interfaces, just to name a few.

It is here that master entrepreneurs and their teams must see beyond the immediate implications of a given technology, capturing second-order, Google-sized business opportunities on the horizon.

Welcome to a new decade of runaway technological booms, historic watershed moments, and extraordinary abundance.

Lets dive in.

(1) Continued increase in global abundance: The number of individuals in extreme poverty continues to drop, as the middle-income population continues to rise. This metatrend is driven by the convergence of high-bandwidth and low-cost communication, ubiquitous AI on the cloud, and growing access to AI-aided education and AI-driven healthcare. Everyday goods and services (finance, insurance, education, and entertainment) are being digitized and becoming fully demonetized, available to the rising billion on mobile devices.

(2) Global gigabit connectivity will connect everyone and everything, everywhere, at ultra-low cost: The deployment of both licensed and unlicensed 5G, plus the launch of a multitude of global satellite networks (OneWeb, Starlink, etc.), allow for ubiquitous, low-cost communications for everyone, everywhere, not to mention the connection of trillions of devices. And todays skyrocketing connectivity is bringing online an additional three billion individuals, driving tens of trillions of dollars into the global economy. This metatrend is driven by the convergence oflow-cost space launches, hardware advancements, 5G networks, artificial intelligence, materials science, and surging computing power.

(3) The average human healthspan will increase by 10+ years:A dozen game-changing biotech and pharmaceutical solutions (currently in Phase 1, 2, or 3 clinical trials) will reach consumers this decade, adding an additional decade to the human healthspan. Technologies include stem cell supply restoration,wnt pathway manipulation, senolytic medicines, a new generation of endo-vaccines, GDF-11, and supplementation of NMD/NAD+, among several others. And as machine learning continues to mature, AI is set to unleash countless new drug candidates, ready for clinical trials. This metatrend is driven by the convergence ofgenome sequencing, CRISPR technologies, AI, quantum computing, and cellular medicine.

(4) An age of capital abundance will see increasing access to capital everywhere: From 2016 2018 (and likely in 2019), humanity hit all-time highs in the global flow of seed capital, venture capital, and sovereign wealth fund investments. While this trend will witness some ups and downs in the wake of future recessions, it is expected to continue its overall upward trajectory. Capital abundance leads to the funding and testing of crazy entrepreneurial ideas, which in turn accelerate innovation. Already, $300 billion in crowdfunding is anticipated by 2025, democratizing capital access for entrepreneurs worldwide. This metatrend isdriven by the convergence of global connectivity, dematerialization, demonetization, and democratization.

(5) Augmented reality and the spatial webwill achieve ubiquitous deployment: The combination of augmented reality (yielding Web 3.0, or the spatial web) and 5G networks (offering 100Mb/s 10Gb/s connection speeds) will transform how we live our everyday lives, impacting every industry from retail and advertising to education and entertainment. Consumers will play, learn, and shop throughout the day in a newly intelligent, virtually overlaid world. This metatrend will be driven by the convergence ofhardware advancements, 5G networks, artificial intelligence, materials science, and surging computing power.

(6) Everything is smart, embedded with intelligence: The price of specialized machine learning chips is dropping rapidly with a rise in global demand. Combined with the explosion of low-cost microscopic sensors and the deployment of high-bandwidth networks, were heading into a decade wherein every device becomes intelligent. Your childs toy remembers her face and name. Your kids drone safely and diligently follows and videos all the children at the birthday party. Appliances respond to voice commands and anticipate your needs.

(7) AI will achieve human-level intelligence:As predicted by technologist and futurist Ray Kurzweil, artificial intelligence will reach human-level performance this decade (by 2030). Through the 2020s, AI algorithms and machine learning tools will be increasingly made open source, available on the cloud, allowing any individual with an internet connection to supplement their cognitive ability, augment their problem-solving capacity, and build new ventures at a fraction of the current cost. This metatrend will bedriven by the convergence ofglobal high-bandwidth connectivity, neural networks, and cloud computing. Every industry, spanning industrial design, healthcare, education, and entertainment, will be impacted.

(8) AI-human collaboration will skyrocket across all professions: The rise of AI as a Service (AIaaS) platforms will enable humans to partner with AI in every aspect of their work, at every level, in every industry. AIs will become entrenched in everyday business operations, serving as cognitive collaborators to employeessupporting creative tasks, generating new ideas, and tackling previously unattainable innovations. In some fields, partnership with AI will even become a requirement. For example: in the future, making certain diagnoses without the consultation of AI may be deemed malpractice.

(9) Most individuals adapt aJARVIS-like software shell to improve their quality of life: As services like Alexa, Google Home, and Apple Homepod expand in functionality, such services will eventually travel beyond the home and become your cognitive prosthetic 24/7. Imagine a secure JARVIS-like software shell that you give permission to listen to all your conversations, read your email, monitor your blood chemistry, etc. With access to such data, these AI-enabled software shells will learn your preferences, anticipate your needs and behavior, shop for you, monitor your health, and help you problem-solve in support of your mid- and long-term goals.

(10) Globally abundant, cheap renewable energy: Continued advancements in solar, wind, geothermal, hydroelectric, nuclear, and localized grids will drive humanity towards cheap, abundant, and ubiquitous renewable energy. The price per kilowatt-hour will drop below onecent per kilowatt-hour for renewables, just as storage drops below a mere three cents per kilowatt-hour, resulting in the majority displacement of fossil fuels globally. And as the worlds poorest countries are also the worlds sunniest, the democratization of both new and traditional storage technologies will grant energy abundance to those already bathed in sunlight.

(11) The insurance industry transforms from recovery after risk to prevention of risk:Today, fire insurance pays youafteryour house burns down; life insurance pays your next-of-kinafteryou die; and health insurance (which is really sick insurance) pays onlyafteryou get sick. This next decade, a new generation of insurance providers will leveragethe convergence of machine learning, ubiquitous sensors, low-cost genome sequencing, and robotics to detect risk,preventdisaster, and guarantee safety before any costs are incurred.

(12) Autonomous vehicles and flying cars will redefine human travel (soon to be far faster and cheaper):Fully autonomous vehicles, car-as-a-service fleets, and aerial ride-sharing (flying cars) will be fully operational in most major metropolitan cities in the coming decade. The cost of transportation will plummet 3-4X, transforming real estate, finance, insurance, the materials economy, and urban planning. Where you live and work, and how you spend your time, will all be fundamentally reshaped by this future of human travel. Your kids and elderly parents will never drive. This metatrend will bedriven by the convergence ofmachine learning, sensors, materials science, battery storage improvements, and ubiquitous gigabit connections.

(13) On-demand production and on-demand delivery will birth an instant economy of things:Urban dwellers will learn to expect instant fulfillment of their retail orders as drone and robotic last-mile delivery services carry products from local supply depots directly to your doorstep. Further riding the deployment of regional on-demand digital manufacturing (3D printing farms), individualized products can be obtained within hours, anywhere, anytime. This metatrend isdriven by the convergence of networks, 3D printing, robotics, and artificial intelligence.

(14) Ability to sense and know anything, anytime, anywhere:Were rapidly approaching the era wherein 100 billion sensors (the Internet of Everything) is monitoring and sensing (imaging, listening, measuring) every facet of our environments, all the time. Global imaging satellites, drones, autonomous car LIDARs, and forward-looking augmented reality (AR) headset cameras are all part of a global sensor matrix, together allowing us to know anything, anytime, anywhere. This metatrend isdriven by the convergence ofterrestrial, atmospheric and space-based sensors, vast data networks, and machine learning. In this future, its not what you know, but rather the quality of the questions you ask that will be most important.

(15) Disruption of advertising:As AI becomes increasingly embedded in everyday life, your custom AI will soon understand what you want better than you do. In turn, we will begin to both trust and rely upon our AIs to make most of our buying decisions, turning over shopping to AI-enabled personal assistants. Your AI might make purchases based upon your past desires, current shortages, conversations youve allowed your AI to listen to, or by tracking where your pupils focus on a virtual interface (i.e. what catches your attention). As a result, the advertising industrywhich normally competes foryourattention (whether at the Superbowl or through search engines)will have a hard time influencing your AI. This metatrend isdriven by the convergence ofmachine learning, sensors, augmented reality, and 5G/networks.

(16) Cellular agriculture moves from the lab into inner cities, providing high-quality protein that is cheaper and healthier: This next decade will witness the birth of the most ethical, nutritious, and environmentally sustainable protein production system devised by humankind. Stem cell-based cellular agriculture will allow the production of beef, chicken, and fishanywhere, on-demand, with far higher nutritional content, and a vastly lower environmental footprint than traditional livestock options. This metatrend isenabled by the convergence ofbiotechnology, materials science, machine learning, and AgTech.

(17) High-bandwidth brain-computer interfaces (BCIs) will come online for public use: Technologist and futurist Ray Kurzweil has predicted that in the mid-2030s, we will begin connecting the human neocortex to the cloud. This next decade will see tremendous progress in that direction, first serving those with spinal cord injuries, whereby patients will regain both sensory capacity and motor control. Yet beyond assisting those with motor function loss, several BCI pioneers are now attempting to supplement their baseline cognitive abilities, a pursuit with the potential to increase their sensorium, memory, and even intelligence. This metatrend is fueled by the convergence ofmaterials science, machine learning, and robotics.

(18) High-resolution VRwill transform both retail and real estate shopping:High-resolution, lightweight virtual reality headsets will allow individuals at home to shop for everything from clothing to real estate from the convenience of their living room. Need a new outfit? Your AI knows your detailed body measurements and can whip up a fashion show featuring your avatar wearing the latest 20 designs on a runway. Want to see how your furniture might look inside a house youre viewing online? No problem! Your AI can populate the property with your virtualized inventory and give you a guided tour. This metatrend isenabled by the convergence of: VR, machine learning, and high-bandwidth networks.

(19) Increased focus on sustainability and the environment:An increase in global environmental awareness and concern over global warming will drive companies to invest in sustainability, both from a necessity standpoint and for marketing purposes. Breakthroughs in materials science, enabled by AI, will allow companies to drive tremendous reductions in waste and environmental contamination. One companys waste will become another companys profit center. This metatrend isenabled by the convergence ofmaterials science, artificial intelligence, and broadband networks.

(20) CRISPR and gene therapies will minimize disease:A vast range of infectious diseases, ranging from AIDS to Ebola, are now curable. In addition, gene-editing technologies continue to advance in precision and ease of use, allowing families to treat and ultimatelycurehundreds of inheritable genetic diseases. This metatrend isdriven by the convergence of various biotechnologies (CRISPR, gene therapy), genome sequencing, and artificial intelligence.

(1) A360 Executive Mastermind:If youre an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. Im committed to running A360 for the course of an ongoing 25-year journey as a countdown to the Singularity.

If youd like to learn more and consider joining our 2020 membership,apply here.

(2) Abundance-Digital Online Community:Ive also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity Universitys onramp for exponential entrepreneurs those who want to get involved and play at a higher level.Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity Universityyour participation opens you to a global community.)

This article originally appeared ondiamandis.com. Read theoriginal article here.

Image Credit: Image by Free-Photos from Pixabay

Here is the original post:
20 Technology Metatrends That Will Define the Next Decade - Singularity Hub

LANL Scientists And International Partners Create 3-D Image Of Heart RNA Structure For First Time – My Blog – Los Alamos Daily Post

The first 3-D images have been created of an RNA molecule known as Braveheart for its role in transforming stem cells into heart cells. Courtesy/LANL

LANL News:

Scientists at Los Alamos National Laboratory and international partners have created the first 3-D images of a special type of RNA molecule that is critical for stem cell programming and known as the dark matter of the genome.

As far as we know, said corresponding author Karissa Sanbonmatsu, this is the first full 3-D structural study of any long, non-coding RNA (lncRNA) other than a partial structure.

Sanbonmatsu is a structural biologist at LANL.

A better understanding of these RNAs could lead to new strategies in regenerative medicine for people with heart conditions due to cardiovascular disease or aging,Sanbonmatsu said.

The team used a technique called small angle X-ray scattering (SAXS) that reveals the 3-D envelope of the RNA molecule, according to Trushar Patel, a Canadian professor on the team. Next, with the help of machine learning and high-performance computing, they made atomistic models to fit inside the envelopes this included the creation of an atomistic model that is also the longest of an isolated RNA (636 nucleotides) to date, said Doo Nam Kim, lead author on the Nature Communications paper.

Our work represents the first step in showing that these difficult-to-image RNAs do possess 3-D structures, and that these molecular structures may very well determine how they operate, Sanbonmatsu said. The RNA studied is called Braveheart it triggers the transformation of stem cells into heart cells.

Before the human genome was sequenced in 2000, it was thought that it mostly contained instructions for proteins, the workhorse molecules of human cells. Scientists were shocked to discover that less than 10 percent of the genome encoded proteins. Ever since, the other 90 percent was deemed to be junk DNA or dark matter. Enter RNA, the molecular cousin of DNA. Scientists originally assumed the main purpose of RNA was simply to coordinate as a messenger for DNA in the synthesis of proteins. However, it has recently been shown that more than 90 percent of the genome encodes a new and mysterous class of RNAs, called long non-coding RNA molecules (lncRNA).

These RNA molecules help to control the turning on and off of genes; their malfunction causes birth defects, autism and even cancer in some cases. They also are key to reprogramming adult stem cells. Even though the molecules make up 90 percent of the genome, scientists have almost no idea how they work, or even what they look like. In this study, one of the largest RNA-only 3-D studies, the new 3-D images sets the stagefor future studies that will shed more light on how they control genes.

Publication:

Zinc-finger protein CNBP alters the 3-D structure of lncRNA Braveheart in solution Authors: Karissa Y. Sanbonmatsu, Doo Nam Kim and Scott P. Hennelly of Los Alamos National Laboratory and New Mexico Consortium; Bernhard C. Thiel and Ivo L. Hofacker of University of Vienna, Austria; Tyler Mrozowich and Trushar R. Patel of University of Lethbridge, Canada. Nature Communications, DOI 10.1038/s41467-019-13942-4

Funding:

National Institutes of Health, Los Alamos Institutional Computing and Los Alamos Laboratory Directed R& D, and Diamond Light Source (UK).

AboutLos Alamos National Laboratory:

Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is operated by Triad, a public service oriented, national security science organization equally owned by its three founding members: Battelle Memorial Institute (Battelle), the Texas A&M University System (TAMUS), and the Regents of the University of California (UC) for the Department of Energys National Nuclear Security Administration.

Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health, and global security concerns.

Go here to read the rest:
LANL Scientists And International Partners Create 3-D Image Of Heart RNA Structure For First Time - My Blog - Los Alamos Daily Post

BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week – Yahoo Finance

NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview at the 2020 Biotech Showcase, being held on January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

Mr. Lebovits will also present at the 3rd Annual Neuroscience Innovation Forum, taking place on January 12, 2020, at the Marines Memorial Club in San Francisco. Additionally, Ralph Kern M.D., MHSc, BrainStorms Chief Operating Officer and Chief Medical Officer, will participate on aRare & Orphan Diseases Panel.

Meetings

BrainStorms senior management will also be hosting institutional investor and partnering meetings at the 2020 Biotech Showcase conference (https://goo.gl/SGFm62). Please use the Investor contact information provided below to schedule a meeting.

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at http://www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Story continues

Excerpt from:
BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - Yahoo Finance

Mesenchymal Stem Cells Market to Perceive Substantial Growth During 2019 to 2027 | Lonza, Thermo Fisher, Bio-Techne, Miltenyi Biotec, PromoCell GmbH,…

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes. The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cell. These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Request Global Mesenchymal Stem Cells Market Research Study Sample

The Global Mesenchymal Stem Cells Market Report profoundly studies past and present phase of the global Mesenchymal Stem Cells market to provide valuable and reliable forecast estimation that drives Mesenchymal Stem Cells market player to obtain comprehensive market scenario for near future. It facilitates Mesenchymal Stem Cells manufacturers and company officials with analysis based on upcoming investment opportunities, challenges, risks, and threats and prompts them to precisely plan their future activities.

Top Leading Vendors :-

Lonza, Thermo Fisher, Bio-Techne, Miltenyi Biotec, PromoCell GmbH, Irvine Scientific, Axol Bioscience, STEMCELL Technologies, Biological Industries, R&D Systems, Inc., Cell Applications, Inc., Cyagen Biosciences Inc., Cytori Therapeutics Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

The report further explains the performance of the Mesenchymal Stem Cells market from the last five years. According to the research the market is expected to dominate international market structure with commendable revenue outcome and it would be one of the most influential markets in the world with heavily escalating annual growth rate.

Ask For Discount on Global Visualization Software Market Study

On the basis of product type, the global Mesenchymal Stem Cells Market is segmented into:

On the basis of application, the global Mesenchymal Stem Cells Market is segmented into:

The report divides the global Mesenchymal Stem Cells market into several significant segments such as Mesenchymal Stem Cells types, applications, technology, end-users, and region. It offers complete and comprehensive cognition for each segment alongside an evaluation of their consumption, sales volume, and revenue outcomes. The proposed segmentation analysis also aids a player to form a customer-oriented approach, make business strategies, and set targets and goals for the firm.

Enquiry before Buying of Global Visualization Software Market

Besides, the report renders such insights that help to determine upcoming business opportunities, challenges, risks, threats, and obstacles; and enables to make informed decisions. It also depicts provincial trade policies, entry barriers, environmental and financial concerns, and other factors that could potentially obstruct Mesenchymal Stem Cells market growth in the future.

Kindly contact us in case of queries or customized data need to be added. sales@reportconsultant.com

Go here to read the rest:
Mesenchymal Stem Cells Market to Perceive Substantial Growth During 2019 to 2027 | Lonza, Thermo Fisher, Bio-Techne, Miltenyi Biotec, PromoCell GmbH,...

Understanding the developmental conditions of the human spine – Tech Explorist

Almost two decades ago, Biologist Olivier Pourqui established the segmental organization of the vertebral column in embryogenesis, when pairs of somites are rhythmically produced by the presomitic mesoderm (PSM). The tempo of somite formation is controlled by a molecular oscillator known as the segmentation clock. Although this oscillator has been well-characterized in model organisms, whether a similar oscillator exists in humans remains unknown.

Along with his colleagues, Olivier now has created the first lab-dish models of the segmentation clock that use stem cells derived from adult human tissue. The team, through this study, confirm that the segmentation clock exists in human also. Moreover, this offers the scientific community the first in vitro system enabling the study of very early spine development in humans.

Pourqui, professor of genetics in the Blavatnik Institute at Harvard Medical School, said, We know virtually nothing about human development of somites, which form between the third and fourth week after fertilization before most people know theyre pregnant. Our system should be a powerful one to study the underlying regulation of the segmentation clock.

Margarete Diaz-Cuadros, a graduate student in the Pourqui lab, said, Our innovative experimental system now allows us to compare mouse and human development side by side. I am excited to unravel what makes human development unique.

The study, in other words, opens up the new pathway towards understanding developmental conditions of the spine, such as congenital scoliosis, as well as diseases involving tissues that arise from the same region of the embryo, known as the paraxial mesoderm.

Scientists became surprised when they found that the segmentation clock began ticking in both the mouse and human cell dishes and that the cells didnt first need to be arranged on a 3D scaffold more closely resembling the body.

The segmentation clock ticks every five hours in the human cells and every 2.5 hours in the mouse cells. The difference in frequency parallels the difference in gestation time between mice and humans.

This work was funded by the National Institutes of Health grant 5R01HD085121 and is published in the Jan. 8 issues of Nature.

See the original post here:
Understanding the developmental conditions of the human spine - Tech Explorist